» Articles » PMID: 24241488

Patient- Versus Physician-reporting of Symptoms and Health Status in Chronic Myeloid Leukemia

Overview
Journal Haematologica
Specialty Hematology
Date 2013 Nov 19
PMID 24241488
Citations 36
Authors
Affiliations
Soon will be listed here.
Abstract

The main objective of this study was to compare the reporting of health status and symptom severity, for a set of core symptoms related to imatinib therapy, between chronic myeloid leukemia patients and their treating physicians. Patients were asked to complete a questionnaire including questions on symptom severity and health status. The symptoms assessed were: abdominal discomfort, diarrhea, edema, fatigue, headache, muscle cramps, musculoskeletal pain, nausea and skin problems. The physicians were asked to complete a questionnaire for each of their patients entering the study. Four hundred twenty-two patients were included in the study. All respective paired physicians (n=29) completed the questionnaire, and thus the analyses are based on 422 patient-physician dyads. Agreement on symptom ratings ranged from 34% (for muscle cramps) to 66% (for nausea). For all symptoms, patients reported higher severity more often than their physicians. The three symptoms whose severity was most frequently underestimated by physicians were fatigue (51%), muscle cramps (49%) and musculoskeletal pain (42%). Health status was overestimated by physicians in 67% of the cases. Physicians and their patients with chronic myeloid leukemia often disagree in their ratings of the patients' symptom severity. Most typically, physicians tend to underestimate symptom severity and overestimate the overall health status of their patients. Current findings support the use of patient-reported outcome measures as a possible means to enhance the management of patients with chronic myeloid leukemia.

Citing Articles

Imatinib therapy of chronic myeloid leukemia significantly reduces carnitine cell intake, resulting in adverse events.

Burda P, Hlavackova A, Polivkova V, Curik N, Laznicka A, Krizkova J Mol Metab. 2024; 88:102016.

PMID: 39182842 PMC: 11403060. DOI: 10.1016/j.molmet.2024.102016.


Physical exercise recommendations for patients with chronic myeloid leukemia based on individual preferences identified in a large international patient survey study of the East German Study Group for Hematology and Oncology (OSHO #97).

Hollenbach L, Rogahn J, le Coutre P, Schulze S, Muegge L, Geissler J Front Oncol. 2024; 14:1345050.

PMID: 38450192 PMC: 10915004. DOI: 10.3389/fonc.2024.1345050.


Real-world use and clinical impact of an electronic patient-reported outcome tool in patients with solid tumors treated with immuno-oncology therapy.

Dickson N, Beauchamp K, Perry T, Roush A, Goldschmidt D, Edwards M J Patient Rep Outcomes. 2024; 8(1):23.

PMID: 38416270 PMC: 10899997. DOI: 10.1186/s41687-024-00700-4.


Patient Reported Outcome Measurement (PROM) under real-life conditions of non-curable cancer outpatients with the Integrated Palliative Outcome Scale (IPOS) and NCCN-Distress Thermometer - A mixed methods study.

Ratzel E, Pretzell I, Kindler T, Weber M, Gerlach C PEC Innov. 2024; 4:100264.

PMID: 38404931 PMC: 10883829. DOI: 10.1016/j.pecinn.2024.100264.


Patient Versus Physician Perspective in the Management of Chronic Myeloid Leukemia During Treatment with Tyrosine Kinase Inhibitors.

Chen H, Wen Y, Zeng Y, Lin L, Sun B, Zhu H Oncol Ther. 2023; 12(1):131-145.

PMID: 38104036 PMC: 10881939. DOI: 10.1007/s40487-023-00255-2.


References
1.
Williams L, Garcia Gonzalez A, Ault P, Mendoza T, Sailors M, Williams J . Measuring the symptom burden associated with the treatment of chronic myeloid leukemia. Blood. 2013; 122(5):641-7. PMC: 3731927. DOI: 10.1182/blood-2013-01-477687. View

2.
Druker B, Guilhot F, OBrien S, Gathmann I, Kantarjian H, Gattermann N . Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006; 355(23):2408-17. DOI: 10.1056/NEJMoa062867. View

3.
Kantarjian H, Hochhaus A, Saglio G, de Souza C, Flinn I, Stenke L . Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial. Lancet Oncol. 2011; 12(9):841-51. DOI: 10.1016/S1470-2045(11)70201-7. View

4.
Detmar S, Muller M, Schornagel J, Wever L, Aaronson N . Health-related quality-of-life assessments and patient-physician communication: a randomized controlled trial. JAMA. 2002; 288(23):3027-34. DOI: 10.1001/jama.288.23.3027. View

5.
Basch E, Jia X, Heller G, Barz A, Sit L, Fruscione M . Adverse symptom event reporting by patients vs clinicians: relationships with clinical outcomes. J Natl Cancer Inst. 2009; 101(23):1624-32. PMC: 2786917. DOI: 10.1093/jnci/djp386. View